Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study

Okamoto, K; Nozawa, H; Hongo, K; Iida, Y; Kawai, K; Sasaki, K; Murono, K; Kita, Y; Ishihara, Y; Takabayashi, N; Kobayashi, R; Hiramatsu, T; Ishihara, S

Okamoto, K (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1,Hongo, Tokyo 1138655, Japan.; Okamoto, K (corresponding author), Yaizu City Hosp, Dept Surg, 1000,Doubara, Yaizu, Shizuoka 4258505, Japan.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021; 26 (8): 1477

Abstract

Background FOLFOX therapy, a standard treatment for colorectal cancer (CRC), causes a rare, but serious adverse event, hyperammonemia. However, the ri......

Full Text Link